WS
HQL

Wedbush Securities’s abrdn Life Sciences Investors HQL Stock Holding History

Wedbush Securities’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$172K Hold
10,600
– – 0.01% 1158
2025
Q4 		$178K Sell
10,600
-350
-3% -$5.88K 0.01% 1133
2025
Q3 		$170K Sell
10,950
-1,000
-8% -$13.7K 0.01% 1091
2025
Q2 		$153K Buy
11,950
+200
+2% +$2.47K 0.01% 1082
2025
Q1 		$149K Buy
+11,750
New +$159K 0.01% 1037
2024
Q4 		– Sell
-16,273
Closed -$245K – 1165
2024
Q3 		$245K Sell
16,273
-400
-2% -$6.05K 0.01% 904
2024
Q2 		$236K Buy
16,673
+1,261
+8% +$17.1K 0.01% 987
2024
Q1 		$210K Sell
15,412
-4,700
-23% -$65K 0.01% 1070
2023
Q4 		$271K Sell
20,112
-2,624
-12% -$32.3K 0.01% 814
2023
Q3 		$284K Buy
22,736
+3,000
+15% +$39.5K 0.01% 754
2023
Q2 		$267K Buy
19,736
+1,724
+10% +$23.8K 0.01% 810
2023
Q1 		$251K Buy
18,012
+1,250
+7% +$17.9K 0.01% 822
2022
Q4 		$238K Buy
16,762
+2,450
+17% +$35.5K 0.01% 834
2022
Q3 		$196K Buy
14,312
+318
+2% +$4.75K 0.01% 902
2022
Q2 		$199K Buy
13,994
+824
+6% +$12.4K 0.01% 929
2022
Q1 		$218K Buy
13,170
+2,975
+29% +$51.2K 0.01% 948
2021
Q4 		$196K Buy
10,195
+109
+1% +$2.19K 0.01% 1062
2021
Q3 		$210K Sell
10,086
-17
-0.2% -$364 0.01% 1042
2021
Q2 		$217K Buy
+10,103
New +$204K 0.01% 1026
2019
Q2 		– Sell
-10,913
Closed -$187K – 1011
2019
Q1 		$187K Buy
+10,913
New +$188K 0.02% 792
2018
Q4 		– Sell
-11,707
Closed -$239K – 882
2018
Q3 		$239K Buy
+11,707
New +$233K 0.03% 686
2016
Q3 		– Sell
-10,104
Closed -$174K – 842
2016
Q2 		$174K Buy
+10,104
New +$186K 0.03% 648
2016
Q1 		– Sell
-12,059
Closed -$285K – 775
2015
Q4 		$285K Buy
12,059
+1,601
+15% +$39.7K 0.05% 426
2015
Q3 		$235K Sell
10,458
-589
-5% -$16.5K 0.05% 465
2015
Q2 		$312K Buy
11,047
+2,105
+24% +$58.3K 0.06% 412
2015
Q1 		$247K Buy
+8,942
New +$244K 0.04% 495

Other funds holding HQL

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Wedbush Securities's HQL Position: Q1 2026 in Review

Wedbush Securities held its abrdn Life Sciences Investors (HQL) position steady in Q1 2026 at 10,600 shares worth $172K. The position accounts for 0.01% of the portfolio, ranked #1158.

Wedbush Securities first reported a position in HQL in Q1 2015 and has held it in 26 quarters since. The position peaked at $312K in Q2 2015. 86 funds tracked by Wall St. Rank hold HQL as of Q1 2026.

  • Wedbush Securities held 10,600 shares of abrdn Life Sciences Investors worth $172K as of Q1 2026.
  • Wedbush Securities left its abrdn Life Sciences Investors share count unchanged in Q1 2026.
  • abrdn Life Sciences Investors made up 0.01% of Wedbush Securities's portfolio in Q1 2026, its #1158 holding.
  • Wedbush Securities first reported a position in abrdn Life Sciences Investors in Q1 2015 and has held it in 26 quarters since.
  • Wedbush Securities's abrdn Life Sciences Investors position peaked at $312K in Q2 2015.
  • 86 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2026.

Based on Wedbush Securities's 13F filing for Q1 2026, filed 21 Apr 2026.